Lu (Maggie) Qian: How Adaptive Trial Design Reveals Treatment Effects in COVID-19
Lu (Maggie) Qian, Founder at Zetyra, Creator and Editor at Evidence in the Wild, shared a post on LinkedIn:
”Four randomized controlled trials of IL-6 receptor antagonists in COVID-19 showed no significant benefit.
Then Remap-cap reported that tocilizumab and sarilumab both worked, with >99.9% posterior probability of superiority and confirmed survival benefit at six months.
The difference wasn’t the drug. It was the design.
Remap-cap used a multifactorial platform design.
Patients were randomized across multiple domains simultaneously, corticosteroids, IL-6 antagonists, anticoagulation, antivirals, convalescent plasma, and a Bayesian model learned which components worked, and for whom, across all domains at once.
Earlier trials enrolled less severely ill patients.
Remap-cap enrolled ICU patients.
It allowed concurrent dexamethasone.
And it had the statistical machinery to isolate the IL-6 effect on top of steroids.
It detected what single-question trials could not.
Then the same platform revealed a different vulnerability.
While the corticosteroid domain was randomizing hydrocortisone vs. no hydrocortisone, the recovery trial announced that dexamethasone reduced mortality.
Overnight, 93% of patients were receiving corticosteroids as background therapy regardless of randomization.
The adaptive engine worked as designed. It just didn’t work fast enough.
A simple, large trial answered the question before the more sophisticated Bayesian platform could.
No amount of pre-specification can fully anticipate the information environment a trial will encounter.
Meanwhile, most Phase III trials use covariate-adaptive randomization, and then analyze the data as though they used simple randomization, leaving power on the table.
Corrected inference methods exist.
The carat R package implements them.
Most practicing biostatisticians haven’t heard of it.
Randomization determines what a trial can learn, not just who gets what treatment.
It should be one of the first design decisions.
Not the last.”
Stay updated with Hemostasis Today.
-
Mar 4, 2026, 15:30Pall T. Onundarson: Risks of Switching Warfarin to DOACs in Frail Elderly Patients with NVAF
-
Mar 4, 2026, 15:25Mital Jhaveri: Key Updates in the 2026 Guideline on Acute Pulmonary Embolism in Adults
-
Mar 4, 2026, 15:14Jean Terrier: The Relationship Between DOAC Plasma Concentrations and Clinical Outcomes
-
Mar 4, 2026, 15:11Rishiraj Sinha: Why Trust Matters More Than Knowledge in Blood Donor Engagement
-
Mar 4, 2026, 15:08Nico Gagelmann: Honored to Receive the Young European Hematology Association Award
-
Mar 4, 2026, 14:45Rafael Demarchi Malgor: New Clinical Practice Guideline on Upper Extremity Deep Venous Thrombosis
-
Mar 4, 2026, 14:44Peter Zdziarski: From a Small Message Board to a Global Glanzmann Thrombasthenia Community
-
Mar 4, 2026, 14:36Abdul Mannan: A Practical Guide to Anticoagulation Stewardship
-
Mar 4, 2026, 14:21Midhuna Krishnan: Simplifying Doppler Effect and Ultrasonography Using the Feynman Method